Effects of inulin‐type fructans with different degrees of polymerization on inflammation, oxidative stress and endothelial dysfunction in women with polycystic ovary syndrome: A randomized, double‐blind, placebo‐controlled trial

Ziaei, Rahele; Shahshahan, Zahra; Tehrani, Hatav Ghasemi; Heidari, Zahra; Ghiasvand, Reza

doi:10.1111/cen.14712

Cited by 13 publications

(6 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the study by Ziaei et al, 75 women with PCOS who were randomly divided into groups received 10 g/day of high-potency inulin (HPI) or oligofructose-enriched inulin (OEI) or placebo for 12 weeks. Based on the results, it was inferred that supplementation with long-chain inulin-type fructans (ITFs) may have a beneficial effect on inflammatory markers in women with PCOS [56]. The values of inflammatory markers (IL-6, TNF-α, CRP) in women with PCOS may also decrease following regular aerobic exercise [57].…”

Section: Discussionmentioning

confidence: 99%

Influence of hsCRP Parameter on the Occurrence of Metabolic Syndrome in Patients with Polycystic Ovary Syndrome

et al. 2023

View full text Add to dashboard Cite

PCOS (polycystic ovary syndrome) is a common endocrine disorder that affects 8–13% of women of reproductive age. Increased body weight and insulin resistance may be associated with chronic inflammation, which increases the risk of cardiovascular complications. CRP (C-reactive protein) tests may be use to assess persistent inflammation. Elevated CRP levels may be associated with insulin resistance and type 2 diabetes. Determination of hsCRP, highly sensitive C-reactive protein, can be used to assess cardiovascular risk in women with PCOS. In this study, 120 women between the ages of 18 and 42 were divided into two groups: patients with polycystic ovary syndrome (n = 80) and regular menstruating women in whom PCOS was excluded (n = 40). Lipid and carbohydrate metabolism parameters and hsCRP levels were assessed, followed by receiver operating characteristic (ROC) analysis for hsCRP, where metabolic syndrome was the dependent variable. For hsCRP, the cutoff point was 1.44 (mg/dL). Sensitivity for the cutoff point was 0.913 and specificity was 0.691. The area under the curve (AUC) was 0.851 (p < 0.000). The closer the AUC value is to unity, the better the predictive ability of the studied variable. There was also a statistically significant correlation between hsCRP levels and the presence of metabolic syndrome.

show abstract

Section: Discussionmentioning

confidence: 99%

Influence of hsCRP Parameter on the Occurrence of Metabolic Syndrome in Patients with Polycystic Ovary Syndrome

et al. 2023

View full text Add to dashboard Cite

show abstract

“…The sample size was calculated using the formula for a randomized controlled trial with a three‐arm parallel design. Considering the effect size reported in similar interventions (Dehghan et al., 2013; Ziaei et al., 2022), a standard effect size of 0.9 was estimated for the main outcomes to detect significant differences between groups. Considering g = 3, α = 0.05, power = 80%, and the standard effect size ≥0.9, a total of 75 subjects was required.

n_{1} goodbreak= ()(, 1 goodbreak+ \sqrt{g - 1}) \frac{{()(, z_{1 - \frac{true}{α}} goodbreak+ z_{1 - β})}^{2}}{∆^{2}} goodbreak+ \frac{z_{1 - \frac{true}{α}}^{2} \sqrt{g - 1}}{2 ()(, 1 goodbreak+ \sqrt{g - 1})} goodbreak= ()(, 1 goodbreak+ \sqrt{3 - 1}) \frac{7.849}{{0.9}^{2}} goodbreak+ \frac{{1.96}^{2} \sqrt{3 - 1}}{2 ()(, 1 goodbreak+ \sqrt{3 - 1})} ≅ 25

n goodbreak= n_{1} goodbreak+ ()(, g goodbreak- 1) n_{2} goodbreak= 25 goodbreak+ ()(, 2 * 25) goodbreak= 75

…”

Section: Methodsmentioning

confidence: 99%

“…The sample size was calculated using the formula for a randomized controlled trial with a three‐arm parallel design. Considering the effect size reported in similar interventions (Dehghan et al., 2013 ; Ziaei et al., 2022 ), a standard effect size of 0.9 was estimated for the main outcomes to detect significant differences between groups. Considering g = 3, α = 0.05, power = 80%, and the standard effect size ≥0.9, a total of 75 subjects was required.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Inulin‐type fructans with different degrees of polymerization improve insulin resistance, metabolic parameters, and hormonal status in overweight and obese women with polycystic ovary syndrome: A randomized double‐blind, placebo‐controlled clinical trial

Ziaei,

Shahshahan,

Ghasemi‐Tehrani

et al. 2023

Food Science & Nutrition

Self Cite

View full text Add to dashboard Cite

Polycystic ovary syndrome (PCOS) is associated with reproductive disorders and adverse cardiometabolic risk factors that can negatively impact the general health of women. Inulin‐type fructans (ITFs) are proposed to beneficially affect risk factors associated with metabolic disorders. Whether ITFs can help with the management of PCOS by modifying insulin resistance (IR) and androgen levels has not yet been explored. The aim of this study was to investigate the effects of ITFs with different degrees of polymerization on insulin resistance, blood lipids, anthropometric measures, and hormonal status in overweight and obese women with PCOS. In a randomized double‐blind placebo‐controlled trial, seventy‐five women with PCOS aged 18–40 years old were randomly assigned to receive 10 g/day of high‐performance inulin (HPI) or oligofructose‐enriched inulin (OEI) or maltodextrin for 12 weeks. Biochemical and clinical outcomes were measured at baseline and after the intervention. Participants in the HPI and OEI groups experienced improvements in waist circumference, total testosterone, free androgen index, sex hormone‐binding globulin, and triglycerides compared to the placebo group. Also, the number of women with irregular menses or oligomenorrhoea decreased significantly in both ITF groups. Participants in the HPI group reported lower body mass, fasting insulin, and HOMA‐IR, as well as a higher quantitative insulin sensitivity check index. ITF supplementation, especially with long‐chain ITFs, when given for 12 weeks may improve metabolic outcomes, androgen status and clinical manifestations in women with PCOS.

show abstract

“…Regarding its molecular structure, inulin is primarily composed of linear β-2,1-linked fructose with a terminal α-1,2-linked glucose residue and a varied degree of polymerization (DP) from 2 to 60. Inulin with a DP < 10 is generally termed short-chain inulin or fructo-oligosaccharide (FOS), and inulin with a DP > 20 is called long-chain inulin [9,10]. Due to the speci c glycosidic bond of the non-alpha-1,4 chemical bond, inulin is not able to be digested by amylase in animals and human gastrointestinal tract.…”

Section: Introductionmentioning

confidence: 99%

Medium-chain inulin alleviates the obesity and improves systemic health in diet-induced obese mice via mediating the gut microbiome and metabolome

Wang,

Kim,

Cui

et al. 2023

Preprint

View full text Add to dashboard Cite

Background Inulin is well known as a natural dietary fiber with multiple beneficial effects on promoting the physiological and intestinal health of hosts. However, it is unclear whether medium-chain inulin can inhibit high-fat diet (HFD)-induced obesity in mice and its mechanism(s) that underlie such effects. In this study, we tested the hypothesis that medium-chain inulin consumption can counteract the obesity in HFD-fed mice by selectively modulating the gut microbiota, metabolome, and metabolic pathways. Results The results shown that the medium-chain inulin is a polymer primarily consisting of fructose linked 2,1 glycosidic bonds with an average degree polymerization of 12. Among them, molecules of different chain lengths form spherical or cross-linked network spatial structures by folding and coiling. Medium-chain inulin supplementation (3% or 5%) reduced lipid deposition in tissues, ameliorated intestinal health, and thus prevented diet-induced obesity in mice. Furthermore, dietary inclusion of inulin shaped a significantly different microbial community by specially increasing the abundances of Bacteroidota, Faecalibaculum, Bifidobacterium, Parasutterella, Lactobacillaceae, Bacteroides, Clostridium_sensu_stricto_1, and Akkermansia in inulin-supplemented groups compared with the HFD group. Additionally, dietary inulin supplementation enhanced the concentrations of nicotinamide, indole-3-acetate, 5-hydroxytryptophan, maltose, taurocholic acid, aldosterone 5α-dihydrotestosterone, and corticosterone in gut content of HFD-fed mice, and thus modulated certain energy utilization-related metabolic pathways. Especially, those significantly modulated microbes and metabolites by inulin supplementation positively correlated with ameliorated healthy parameters. Therefore, medium-chain inulin inhibits HFD-induced obesity by specifically modulating key gut microbes and metabolites, thereby affecting the inulin-gut microbiota/metabolome-tissue (phenotype) axis. Conclusions Taken together, dietary inulin supplementation improved the gut barrier and physiological health, while alleviated HFD-induced obesity and complications of mice, including fat deposition and metabolic disorders, etc. This beneficial effect was attributed to the fact that feeding medium-chain inulin could specifically promote certain key beneficial gut bacteria and metabolites, and thus arouse energy utilization-related metabolic pathways alteration. Thus, medium-chain inulin can be employed as a potential functional food or therapeutic agent to prevent or treat diet-induced obesity in the host.

show abstract

Effects of inulin‐type fructans with different degrees of polymerization on inflammation, oxidative stress and endothelial dysfunction in women with polycystic ovary syndrome: A randomized, double‐blind, placebo‐controlled trial

Cited by 13 publications

References 40 publications

Influence of hsCRP Parameter on the Occurrence of Metabolic Syndrome in Patients with Polycystic Ovary Syndrome

Influence of hsCRP Parameter on the Occurrence of Metabolic Syndrome in Patients with Polycystic Ovary Syndrome

Inulin‐type fructans with different degrees of polymerization improve insulin resistance, metabolic parameters, and hormonal status in overweight and obese women with polycystic ovary syndrome: A randomized double‐blind, placebo‐controlled clinical trial

Medium-chain inulin alleviates the obesity and improves systemic health in diet-induced obese mice via mediating the gut microbiome and metabolome

Contact Info

Product

Resources

About